Viatris Inc. (VTRS)

Market Cap	17.79B +40.5%
Revenue (ttm)	14.30B -3.0%
Net Income	-3.51B
EPS	-3.00
Shares Out	1.15B
PE Ratio	n/a
Forward PE	6.32
Dividend	$0.48 (3.11%)
Ex-Dividend Date	Mar 9, 2026

Volume	1,199,809
Open	15.16
Previous Close	15.25
Day's Range	15.16 - 15.47
52-Week Range	6.85 - 16.47
Beta	0.80
Analysts	Hold
Price Target	11.83 (-23.43%)
Earnings Date	Feb 26, 2026

About VTRS

Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1961
• Employees: 32,000
• Stock Exchange: NASDAQ
• Ticker Symbol: VTRS
• Website: https://www.viatris.com

Financial Performance

In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price target is $11.83, which is a decrease of -23.43% from the latest price.

Price Target

$11.83

(-23.43% downside)

Analyst Consensus: Hold